REGN Q2 2017 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

REGNRegeneron Pharmaceuticals, Inc.

$81B

Q2 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1.5B+21.2% YoY

Gross Profit

$1.3B90.6% margin

Operating Income

$550M37.4% margin

Net Income

$388M26.4% margin

EPS (Diluted)

$3.34

QoQ Revenue Growth

+11.5%

Cash Flow

Operating Cash Flow

-$31M

Free Cash Flow

-$85M

Stock-Based Comp.

$121M

Balance Sheet

Total Assets

$8.1B

Total Liabilities

$2.6B

Stockholders' Equity

$5.5B

Cash & Equivalents

$744M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.5B	$1.2B	+21.2%
Gross Profit	$1.3B	$1.1B	+16.5%
Operating Income	$550M	$292M	+88.7%
Net Income	$388M	$196M	+97.6%

Revenue Segments

Antibody Collaboration

$133M60%

Immuno-oncology Agreement

$89M40%